Proveedores de Foundayo (Orforglipron) en 2026 — Clasificados y Revisados
Foundayo (orforglipron, fabricado por Eli Lilly) es la primera tableta GLP-1 oral diaria aprobada por la FDA para el manejo del peso —sin restricciones de comida ni agua, sin pluma para inyectar. Mostramos qué proveedores de telesalud y farmacias la ofrecen ahora, precios mensuales, dosis disponibles y cobertura por estado, para que sepas dónde conseguirla legítimamente.
WeightLossRankings.org se sostiene gracias a sus lectores. Cuando compras a través de enlaces en nuestro sitio, podemos ganar una comisión de afiliados. Más información
16 proveedores de foundayo (orforglipron) comparados · puntuados de forma independiente según nuestra metodología de seis factores.
Cómo clasificamos y qué cuenta como “legítimo”
Cada proveedor en esta clasificación se puntúa contra nuestra rúbrica de seis factores[1] publicada — valor, eficacia, experiencia del usuario, confianza y seguridad, accesibilidad y soporte.
Wegovy, Zepbound, Ozempic y Mounjaro de marca están aprobados por la FDA bajo sus propios números de NDA[4][5]. La eficacia publicada de Fase 3 para semaglutida 2.4 mg (~14.9% de pérdida de peso promedio en 68 semanas) proviene del ensayo STEP 1[6], y para tirzepatida (~20.9% en dosis de 15 mg durante 72 semanas) del SURMOUNT-1[7]; el SURMOUNT-5 comparativo publicado en 2025 comparó las dos directamente[8].
La cobertura del seguro para medicamentos contra la obesidad varía ampliamente por programa de Medicaid estatal y plan comercial[9][10]. Los GLP-1 compuestos y de marca generalmente son elegibles para FSA/HSA con receta médica según la Publicación 502 del IRS[11].
Selecciones rápidas: Top 5
Reseñas detalladas
Amazon One Medical
Mejor para: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
Amazon One Medical is the unified Amazon GLP-1 channel — One Medical clinicians prescribe FDA-approved Wegovy, Zepbound, and Foundayo (no compounded products), and Amazon Pharmacy fulfills with same-day delivery across roughly 3,000 US cities plus pickup kiosks at select One Medical locations. No prior membership required; insurance and cash pay both accepted. Foundayo launched at $25/month with insurance and the Lilly Savings Card, or $149/month cash pay.
Desglose de puntuación
Pros
- ✓As low as $1/day ($25/month) for brand-name Foundayo with insurance and the auto-applied Lilly coupon
- ✓Same-day delivery in nearly 3,000 US cities at launch, expanding to 4,500 by end of 2026
- ✓In-office pharmacist kiosks at select One Medical clinics let you walk out with Foundayo in hand
- ✓Cash-pay $5/day ($149/month) is competitive for the same FDA-approved brand-name product
- ✓Real-time availability, transparent pricing, and automatic manufacturer coupon at checkout
- ✓Delivering GLP-1 medications since 2021 — track record on cold-chain logistics
Contras
- ✗Headline $25/month needs both insurance and the Lilly Savings Card — uninsured pay $149/month
- ✗Same-day delivery is geographically gated; outside major cities it drops to next-day or slower
- ✗Pricing is set by manufacturer savings programs and can change at any time
- ✗No compounded options — brand-name only (Foundayo, Wegovy, Zepbound)
- ✗Wegovy/Zepbound pricing isn't shown upfront — depends on insurance at the prescribing visit
- ✗Copays and deductibles still apply to the clinical visit
LillyDirect Foundayo
Mejor para: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Desglose de puntuación
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Contras
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
ShedRx
Verified partnerMejor para: mainstream telehealth GLP-1 access
Telehealth provider offering compounded GLP-1 medications in injectable, lozenge, and drop formats.
Desglose de puntuación
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Contras
- ✗Limited public information on program details
Calibrate Health
Mejor para: year-long coaching wrap around insured branded GLP-1s
Calibrate Health is a year-long metabolic-reset program pairing branded GLP-1 medication (Wegovy, Ozempic, Zepbound, or Foundayo) with 1:1 video coaching and dietitian support — a deeper clinical wrap than transactional telehealth. It's branded-only, with a money-back guarantee tied to outcomes. The $199/month program fee runs separately from medication, which can drop to about $25/month with insurance and a savings card.
Desglose de puntuación
Pros
- ✓Year-long program with 1:1 video coaching, dietitian support, and behavior-change curriculum — a deeper clinical wrap than transactional telehealth
- ✓$199/month program fee is competitive; medication co-pay can drop to ~$25/month with insurance and a manufacturer savings card
- ✓Branded GLP-1s only (Wegovy, Ozempic, Zepbound, Foundayo) — no compounded products
- ✓Insurance navigation team works to maximize coverage and reportedly accepts most major commercial plans
- ✓Money-back guarantee tied to a 10% weight-loss outcome over the program year
- ✓Publishes 3-year outcomes data (19% mean weight loss)
Contras
- ✗Medication cost is on top of the $199/month fee; cash-pay patients face full manufacturer pricing
- ✗Insurance navigation only helps if your plan actually covers branded GLP-1s for weight loss — many don't
- ✗Meaningfully more expensive than compounded telehealth if your insurance denies coverage
- ✗Distinct from 'Oxford's Medical Weight Loss (The Calibrate Clinic)' — don't confuse the two
- ✗Initial 3-month commitment required ($597 total, billed as $199/mo) before it renews month-to-month — more lock-in than month-to-month rivals
GoodRx
Mejor para: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Offers self-pay discount pricing for brand-name GLP-1 medications — Foundayo (orforglipron) starting at $149/month and Zepbound KwikPen (tirzepatide) starting at $299/month — redeemable at 70,000+ pharmacies nationwide. Also operates GoodRx Care, a telehealth arm offering GLP-1 prescriptions with online visits starting at $39.
Desglose de puntuación
Pros
- ✓$149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- ✓$299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- ✓Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- ✓No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded
- ✓Manufacturer-direct pricing — Lilly delivers the discount through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth offers GLP-1 prescriptions ($39–$70 per visit, $19 with Gold) — one-stop for script plus card
Contras
- ✗Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- ✗Self-pay only — does not apply toward insurance benefits or deductibles
- ✗Headline price applies to the lowest Foundayo dose; higher doses may cost more
- ✗No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- ✗Pricing can change as Lilly's manufacturer coupon program evolves
PreventiveMD
Mejor para: compounded GLP-1s from $83/mo all-in with brand Wegovy and Zepbound upgrade paths
PreventiveMD is a physician-guided telehealth platform for GLP-1 weight loss and peptide therapy, offering compounded semaglutide from $83/mo all-in and compounded tirzepatide from $97/mo all-in, plus brand Wegovy, Zepbound, and Foundayo on a membership model. A US-licensed provider reviews each request within 24 hours; approved medication ships to your door with ongoing care through an online portal.
Desglose de puntuación
Pros
- ✓Compounded semaglutide from $83/mo and tirzepatide from $97/mo, billed as one all-in monthly price
- ✓Brand Wegovy, Zepbound, and Foundayo (oral GLP-1) available on the same platform
- ✓US-licensed provider reviews requests within 24 hours — no video visit required
- ✓You aren't charged until a provider approves; checkout places an authorization hold only
- ✓LegitScript-certified; works exclusively with state-licensed US 503A compounding pharmacies
- ✓HSA/FSA-eligible with receipts you can submit to your insurer
- ✓Publishes its state-availability list openly on the site
Contras
- ✗Individual compounding pharmacy partners are not publicly named
- ✗Not available in 14 states + DC, including New York, New Jersey, Virginia, and Wisconsin
- ✗Brand Wegovy, Zepbound, and Foundayo require a $49/mo membership fee on top of medication cost
- ✗'As low as' pricing — actual monthly cost can be higher depending on your plan
- ✗Orders become non-refundable once provider review or pharmacy fulfillment begins
Knownwell
Mejor para: Patients wanting branded GLP-1s with obesity-medicine oversight and insurance options
Knownwell is a weight-inclusive metabolic and primary care company co-founded by obesity-medicine specialist Dr. Angela Fitch. It offers branded GLP-1 medications including Wegovy, Zepbound, Ozempic and Saxenda, plus the oral GLP-1 Foundayo, via virtual visits in all 50 states and in-person clinics in Boston, Chicago, Dallas-Fort Worth and Atlanta. Knownwell is a LillyDirect care provider and a Novo Nordisk telehealth partner for the Wegovy pill. Care combines physician oversight with dietitians and coaches. Many insurance plans are accepted, with copays as low as $25 for covered patients.
Desglose de puntuación
Pros
- ✓Co-founded by obesity-medicine specialist Dr. Angela Fitch
- ✓Branded FDA-approved GLP-1s (Wegovy, Zepbound, Ozempic, Saxenda)
- ✓Official LillyDirect provider and Novo Wegovy-pill telehealth partner
- ✓Accepts insurance, copays as low as $25 for covered patients
- ✓Weight-inclusive care with dietitians and health coaches
- ✓Both virtual (50 states) and in-person clinic options
Contras
- ✗Specific self-pay monthly medication prices not transparently posted
- ✗In-person clinics limited to four metro areas
- ✗Branded-only focus can mean higher cost than compounded routes
Ro
Mejor para: broadest GLP-1 formulary including Foundayo on day-one of launch
Ro is one of the largest direct-to-patient telehealth companies in the US and operates the most comprehensive obesity care formulary in the category — compounded semaglutide, brand-name Wegovy and Zepbound, and as of April 9 2026, Eli Lilly's new oral GLP-1 Foundayo (orforglipron) starting at $149/month for the lowest dose plus membership.
Desglose de puntuación
Pros
- ✓One of the broadest GLP-1 menus: compounded semaglutide, brand Wegovy, brand Zepbound, and oral Foundayo (orforglipron)
- ✓Among the first telehealth platforms to offer oral Foundayo at launch (April 2026)
- ✓A licensed provider helps you pick the best GLP-1 based on cost, insurance, and your health goals
- ✓Nationwide delivery, including 99% of primary-care deserts
- ✓Both cash-pay and insurance-eligible options on one platform
Contras
- ✗Foundayo requires a recurring membership on top of the $149/mo drug price, so total cost runs higher
- ✗Foundayo pricing above the lowest dose isn't shown until intake
- ✗State availability and pharmacy partners aren't listed publicly — confirmed at signup
- ✗Membership and medication are billed separately, which can make the true monthly cost confusing
WeightWatchers
Mejor para: Foundayo access with a structured behavior-change program
WeightWatchers offers Foundayo (orforglipron) through its Med+ program, with care delivered by the WeightWatchers Clinic affiliate medical group. Foundayo is self-pay at $149/mo for the starting dose and up to $299/mo at higher doses, billed separately from the Med+ membership ($25 first month, $74/mo after with a 12-month commitment). WW is one of the few non-pharmacy telehealth programs that lists Foundayo transparently.
Desglose de puntuación
Pros
- ✓One of the first non-pharmacy telehealth programs to list Foundayo transparently
- ✓Care delivered by WeightWatchers Clinic (affiliated medical group)
- ✓Supports all 6 Foundayo doses: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg
- ✓Publishes self-pay drug price on the product page (rare for a telehealth program)
- ✓Combines pharmacotherapy with the WW Points/behavior-change program
Contras
- ✗Med+ membership ($25 first month, $74/mo ongoing) is billed separately from the drug cost — actual out-of-pocket is higher than the listed $149/mo
- ✗State availability list not published publicly — requires eligibility quiz
- ✗Insurance coverage for Foundayo not yet available per WW's own disclosure
- ✗No compounded GLP-1 option; Foundayo only
- ✗12-month Med+ commitment required to lock the introductory $25 price
Kin Meds
Mejor para: compounded and brand-name GLP-1 plus a longevity stack on one platform
Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and pill, Zepbound and Foundayo from $149/mo. Beyond weight loss, it bundles a longevity and wellness menu — Sermorelin, NAD+, glutathione, TRT, plus hair, skin and sexual health — so members can manage multiple protocols on one account.
Desglose de puntuación
Pros
- ✓Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- ✓Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- ✓LegitScript verified
- ✓Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- ✓Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
- ✓Telehealth flow clearly disclosed: questionnaire, provider review, tailored plan, ongoing support
Contras
- ✗Legal entity name and state of incorporation not publicly disclosed
- ✗The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- ✗Per-state availability not listed
- ✗$149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- ✗Lab work and dose-titration support not clearly described
- ✗Breadth across 8+ categories signals a broad DTC platform, not a GLP-1 specialist
Hello Alpha
Mejor para: Branded GLP-1s (and oral Foundayo) with insurance support on an established telehealth platform
Hello Alpha (formerly Alpha Medical) is a US telehealth platform offering a full weight-loss lineup: branded GLP-1s including Wegovy, Ozempic, Rybelsus, Zepbound and Mounjaro, plus the oral GLP-1 Foundayo and other oral weight-loss medications. It works with insurance and provides ongoing clinician care through an online membership. Specific cash pricing and the full state list are not enumerated on the public site.
Desglose de puntuación
Pros
- ✓Full branded GLP-1 lineup: Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro
- ✓Offers the oral GLP-1 Foundayo plus oral weight-loss medications
- ✓Works with insurance
- ✓Ongoing clinician care via online membership
Contras
- ✗Cash pricing is not published on the public site
- ✗Full state list is not enumerated
- ✗Insurance coverage of the medication still depends on your plan
MedLeanRx
Mejor para: Texas-only compounded semaglutide at $149/mo with a brand Wegovy and Zepbound pathway
MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX. It prescribes compounded semaglutide as a weekly injection or daily oral tablet at $149/month and compounded tirzepatide at $269/month, plus a brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/month fee where medication is billed separately. A 5-minute online assessment gets a 24-48 hour physician review, with free shipping and cancel-anytime plans.
Desglose de puntuación
Pros
- ✓Compounded semaglutide $149/mo in both weekly injection and daily oral tablet form
- ✓Brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/mo fee plus medication cost
- ✓Intro bundle: 2 months of compounded tirzepatide (2 mg weekly) for $325 — about $163/mo
- ✓LegitScript seal displayed; named supervising physician (Dr. Johnson Uzor, MD)
- ✓Free shipping, no hidden fees, and cancel-anytime plans per homepage trust chips
- ✓5-minute online assessment with 24-48 hour physician review — 100% online, no clinic visits
Contras
- ✗Texas only — not available in the other 49 states
- ✗Compounded tirzepatide is $269/mo at standard pricing, above the ~$249 market median
- ✗Strict no-refund policy: 'All sales are final' per Terms & Conditions
- ✗Pharmacy partner not publicly named — a transparency gap for a compounding service
- ✗Legal entity name and founding details not published on the site
- ✗Brand-medication total cost not published — $99/mo fee plus the separate cost of medication
PrideRx
Mejor para: Brand-name-only GLP-1s (Zepbound, Wegovy Pill, Foundayo) fulfilled by LillyDirect and NovoCare
PrideRx is an LGBTQ+-friendly telehealth platform offering brand-name-only GLP-1 weight loss — Zepbound (tirzepatide) from $299/mo, Wegovy Pill (oral semaglutide) from $149/mo, and Foundayo (orforglipron) from $149/mo — fulfilled directly by LillyDirect and NovoCare. Membership is $25 the first month, then $99/mo, covering doctor visits and prescription management; medication is billed separately by the pharmacy. The platform also covers sexual health, PrEP, and hair loss.
Desglose de puntuación
Pros
- ✓All three brand-name GLP-1 options on one platform — Zepbound injection, Wegovy Pill, and Foundayo — no compounded substitutes
- ✓Medication ships from and is billed by LillyDirect or NovoCare; PrideRx never handles or re-sells the drug
- ✓Transparent published per-dose pricing with on-page verification dates
- ✓$99/mo membership includes doctor visits and prescription management; 24-hour prescription review
Contras
- ✗$99/mo membership on top of medication cost — all-in runs $248–$548/mo depending on drug and dose
- ✗Legal entity and prescribing medical group are not named on the site
- ✗No LegitScript certification visible
- ✗State availability is not published — telehealth consult rules vary by state
FuturHealth
Mejor para: brand-name and compounded GLP-1s with registered-dietitian coaching
FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added Q2 2026) plus clinician-discretionary compounded GLP-1/GIP combinations, dispensed through US-based licensed pharmacies. The platform layers digital coaching and registered-dietitian nutrition guidance on top of the medication.
Desglose de puntuación
Pros
- ✓LegitScript Certified and HITRUST Certified
- ✓Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- ✓Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- ✓Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Contras
- ✗Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- ✗BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- ✗Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- ✗Pricing not shown until after the qualification questionnaire or portal login
- ✗Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
AVARA Rx
Mejor para: 50-state compounded GLP-1 with named pharmacy and clinical network
AVARA Rx is a nationwide DTC telehealth platform offering compounded semaglutide and tirzepatide plus brand-name Wegovy, Zepbound, and Foundayo consultations, alongside HRT, TRT, and longevity add-ons. It openly names both its pharmacy partner and its clinical network — well above the typical transparency floor — and is available in all 50 states, cash-pay only. Compounded semaglutide starts at $229/month and tirzepatide at $279/month.
Desglose de puntuación
Pros
- ✓Names its pharmacy partner (DiRx Health, Ft Lauderdale FL) — buyers can independently verify its licensure
- ✓Names its clinical network (Beluga Health) — you can research the platform handling your prescriptions
- ✓All 50 states explicitly listed on the FAQ — uncommon vs peers that just say 'nationwide'
- ✓Patient-friendly refunds — full refund if a provider disqualifies you, partial if a weaker dose is prescribed
- ✓LegitScript verification badge displayed; pharmacy claims NABP-accredited facilities
- ✓Brand consultations (Wegovy, Wegovy pill, Zepbound, Foundayo) available alongside compounded options
- ✓Adjunct HRT, TRT, and longevity stack (Sermorelin, NAD+, Glutathione) for a broader wellness platform
Contras
- ✗Operating legal entity not disclosed — only a Sheridan, WY registered-agent-style address surfaced
- ✗Dose pricing not itemized — only 'starting at $229' semaglutide and 'starting at $279' tirzepatide
- ✗LegitScript certification number not shown — badge only, so no direct lookup
- ✗No named medical director (Beluga Health is the network, not a named MD)
- ✗Lab work requirements not specified, and consultation fee not broken out from medication cost
- ✗Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed
- ✗Mid-tier pricing ($229/$279) vs lower-priced compounded peers ($99–$179)
PauseRX
Mejor para: explicit 503A pharmacy and physician-network disclosure
PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and publishes a full FDA compounded-medication disclaimer. Despite the name, it isn't menopause-specific. Compounded semaglutide is a flat $199/mo at all doses and tirzepatide starts at $249/mo, with brand Wegovy, Zepbound, and Foundayo also available.
Desglose de puntuación
Pros
- ✓Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
- ✓Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
- ✓Publishes the FDA compounded-medication disclaimer
- ✓Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
- ✓Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation
- ✓Billed at ship, not at order — lower upfront cash exposure
- ✓LegitScript badge displayed
- ✓Adjunct longevity products (NAD+, Glutathione, Sermorelin) for a broader wellness stack
Contras
- ✗States served not listed — site claims nationwide, but you must contact support to confirm availability
- ✗Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
- ✗No named medical director (Beluga Health is the network, not a named MD)
- ✗LegitScript certification number not shown — badge only, so no direct lookup
- ✗Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed
- ✗Corporate physical address not provided
- ✗Despite the 'Pause' name, not positioned as menopause-specific care
- ✗Brand Wegovy, Zepbound, and Foundayo are consultations only, not direct dispensing
Clasificaciones relacionadas
Preguntas frecuentes
Fuentes y metodología — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.